IL226095A - History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them - Google Patents
History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing themInfo
- Publication number
- IL226095A IL226095A IL226095A IL22609513A IL226095A IL 226095 A IL226095 A IL 226095A IL 226095 A IL226095 A IL 226095A IL 22609513 A IL22609513 A IL 22609513A IL 226095 A IL226095 A IL 226095A
- Authority
- IL
- Israel
- Prior art keywords
- pyrrolo
- pyrazol
- pyrimidin
- pyridin
- medicaments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102010050558A DE102010050558A1 (de) | 2010-11-05 | 2010-11-05 | 1H-Pyrrolo[2,3-b]pyridinderivate |
PCT/EP2011/005127 WO2012059172A1 (fr) | 2010-11-05 | 2011-10-12 | Dérivés de 1h-pyrrolo[2,3-b]pyridine |
Publications (2)
Publication Number | Publication Date |
---|---|
IL226095A0 IL226095A0 (en) | 2013-06-27 |
IL226095A true IL226095A (en) | 2016-03-31 |
Family
ID=44897681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL226095A IL226095A (en) | 2010-11-05 | 2013-05-01 | History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them |
Country Status (11)
Country | Link |
---|---|
US (3) | US8664236B2 (fr) |
EP (1) | EP2635574B1 (fr) |
JP (1) | JP5891234B2 (fr) |
CN (1) | CN103180320B (fr) |
AR (1) | AR083751A1 (fr) |
AU (1) | AU2011325480B2 (fr) |
CA (1) | CA2816896C (fr) |
DE (1) | DE102010050558A1 (fr) |
ES (1) | ES2525172T3 (fr) |
IL (1) | IL226095A (fr) |
WO (1) | WO2012059172A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010050558A1 (de) * | 2010-11-05 | 2012-05-10 | Merck Patent Gmbh | 1H-Pyrrolo[2,3-b]pyridinderivate |
DE102010053347A1 (de) * | 2010-12-03 | 2012-06-06 | Merck Patent Gmbh | 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren |
WO2013172872A1 (fr) * | 2012-05-15 | 2013-11-21 | Calasia Pharmaceuticals, Inc. | Dérivés de pyrimidinediamine utilisés en tant qu'inhibiteurs de la hsp90 cytosolique |
EP2738172A1 (fr) * | 2012-11-28 | 2014-06-04 | Almirall, S.A. | Nouveaux composés bicycliques utilisés comme modulateurs du canal crac |
RS63190B1 (sr) | 2014-08-04 | 2022-06-30 | Nuevolution As | Opciono fuzionisani derivati pirimidina zamenjeni heterociklilom korisni za lečenje zapaljenskih, metaboličkih, onkoloških i autoimunskih bolesti |
US20170298060A1 (en) * | 2016-04-18 | 2017-10-19 | Innov17 Llc | Pyrrolopyridine retinoic acid receptor-related orphan receptor modulators and uses thereof |
WO2021124277A1 (fr) | 2019-12-20 | 2021-06-24 | Nuevolution A/S | Composés actifs vis-à-vis des récepteurs nucléaires |
WO2021198955A1 (fr) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Composés actifs vis-à-vis des récepteurs nucléaires |
US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
WO2022203399A1 (fr) * | 2021-03-26 | 2022-09-29 | 주식회사 스탠다임 | Antagoniste du récepteur a2a de l'adénosine et son utilisation |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
GB9904387D0 (en) | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
DE102006012617A1 (de) * | 2006-03-20 | 2007-09-27 | Merck Patent Gmbh | 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
JP2009541318A (ja) * | 2006-06-22 | 2009-11-26 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害剤 |
DE102007028515A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
DE102008031517A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
UY32158A (es) * | 2008-10-03 | 2010-04-30 | Astrazeneca Ab | Derivados heterociclicos y metodos de uso de los mismos |
DE102008052943A1 (de) * | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
DE102009060174A1 (de) * | 2009-12-23 | 2011-06-30 | Merck Patent GmbH, 64293 | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
DE102010050558A1 (de) * | 2010-11-05 | 2012-05-10 | Merck Patent Gmbh | 1H-Pyrrolo[2,3-b]pyridinderivate |
-
2010
- 2010-11-05 DE DE102010050558A patent/DE102010050558A1/de not_active Withdrawn
-
2011
- 2011-10-12 EP EP11773397.2A patent/EP2635574B1/fr not_active Not-in-force
- 2011-10-12 WO PCT/EP2011/005127 patent/WO2012059172A1/fr active Application Filing
- 2011-10-12 JP JP2013537018A patent/JP5891234B2/ja not_active Expired - Fee Related
- 2011-10-12 CA CA2816896A patent/CA2816896C/fr not_active Expired - Fee Related
- 2011-10-12 AU AU2011325480A patent/AU2011325480B2/en not_active Ceased
- 2011-10-12 ES ES11773397.2T patent/ES2525172T3/es active Active
- 2011-10-12 US US13/883,411 patent/US8664236B2/en not_active Expired - Fee Related
- 2011-10-12 CN CN201180053259.7A patent/CN103180320B/zh not_active Expired - Fee Related
- 2011-11-04 AR ARP110104105A patent/AR083751A1/es not_active Application Discontinuation
-
2013
- 2013-05-01 IL IL226095A patent/IL226095A/en not_active IP Right Cessation
- 2013-10-02 US US14/044,330 patent/US8895575B2/en not_active Expired - Fee Related
-
2014
- 2014-08-13 US US14/458,759 patent/US9238651B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2011325480A1 (en) | 2013-05-02 |
DE102010050558A1 (de) | 2012-05-10 |
JP2013541565A (ja) | 2013-11-14 |
US8664236B2 (en) | 2014-03-04 |
US20130231519A1 (en) | 2013-09-05 |
CA2816896C (fr) | 2019-01-08 |
ES2525172T3 (es) | 2014-12-18 |
CN103180320B (zh) | 2015-10-07 |
CA2816896A1 (fr) | 2012-05-10 |
CN103180320A (zh) | 2013-06-26 |
AU2011325480B2 (en) | 2015-03-26 |
EP2635574A1 (fr) | 2013-09-11 |
US20140371215A1 (en) | 2014-12-18 |
IL226095A0 (en) | 2013-06-27 |
US20140100221A1 (en) | 2014-04-10 |
WO2012059172A1 (fr) | 2012-05-10 |
JP5891234B2 (ja) | 2016-03-22 |
AR083751A1 (es) | 2013-03-20 |
US8895575B2 (en) | 2014-11-25 |
US9238651B2 (en) | 2016-01-19 |
EP2635574B1 (fr) | 2014-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL226095A (en) | History of {4– [5– (1-methyl– h1– pyrazole – 4 – ram) - h1– pyrrolo [3,2– b] pyridin-3-ram] pyrimidin-2-yl} reliable and medications containing them | |
ZA201906379B (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
HK1253364B (zh) | 1h-吡唑並[3,4-b]吡啶及其治療應用 | |
HRP20181785T1 (hr) | Proces za pripremanje metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata za uporabu kao farmaceutski aktivnog sastojka | |
ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
IL238493B (en) | Amino-substituted imidazo[a–2,1]pyridinecarboxamides and their use | |
IL223253B (en) | History of 2-(piperidin-2-yl)-pyrazolo[1,5-a]pyrimidine and their use in the preparation of drugs against pneumovirina | |
IL227496B (en) | Pyrazolo[4,3–b]pyridines are converted as drugs | |
SI2529756T1 (sl) | Formulacija vsadka z risperidonom in/ali paliperidonom | |
ZA201405070B (en) | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors | |
IL219861A0 (en) | Process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate and its purification for use as pharmaceutically active compound | |
ZA201307511B (en) | Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
MM9K | Patent not in force due to non-payment of renewal fees |